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ABSTRACT
Introduction: Lenalidomide is an active agent
that was approved for use in the EU in 2015 as a
first-line therapy for previously untreated,
non-transplant eligible multiple myeloma
patients. Our objective was to assess the cost
impact of lenalidomide when selected as a
first-line treatment for transplant-ineligible
patients in France, Germany, Italy, Spain, and
the United Kingdom (EU5).
Methods: We developed a cost-impact model of
the total costs associated with newly diagnosed
multiple myeloma over 5 years in the EU5 based
on treatment duration and time to progression
(TTP) (taken from trial data). We compared a
baseline scenario (of current lenalidomide
uptake) with two alternative future scenarios.
Future Scenario A used an increased uptake of
first-line lenalidomide: up to 50% in Year 5.
Future Scenario B was similar to the baseline,
but included a 20% increased uptake of the
triple therapy regimen, carfilzomib,
lenalidomide, and dexamethasone (KRd) at
second line.
Results: Compared to alternative first-line care
pathways, lenalidomide provides a time to
progression advantage of up to 5.1 months. In
the baseline scenario, the costs per patient were
€40,692 in Year 1. Future Scenario A showed an
additional expenditure of €867 per patient in
Year 1, increasing to €3358 per patient by Year
5, a 2.1% and 8.2% increase from baseline,
respectively. However, lenalidomide use was
associated with a lower monthly
hospitalisation per-patient cost (€813)
compared with bortezomib (€1173) and
thalidomide (€1532). Future Scenario B was
associated with a 29% increase in cost.
Conclusions: Compared to other first line
therapies, lenalidomide delays time to
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progression resulting in associated savings
across a patient’s treatment pathway and
overall is likely to result in a limited impact
on budget. Lenalidomide should, therefore, be
considered as a first treatment option for
multiple myeloma patients ineligible for
transplant.
Funding: Celgene Ltd.
Keywords: Budget impact; Cost impact; First
line; Lenalidomide; Multiple myeloma; Newly
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INTRODUCTION
Multiple myeloma is an incurable haematologic
cancer, accounting for 1% of all cancers and
approximately 10% of all haematologic
malignancies [1]. The treatment paradigm of
induction followed by maintenance to
progression has now been clearly
demonstrated to increase progression-free
survival (PFS) and overall survival (OS).
However, myeloma management is
complicated because nearly all patients relapse
and become refractory [2]. Clinicians must
consider several factors when making
treatment decisions: patient preference and
access to treatment, age, comorbidities and
frailty [3].
Lenalidomide is an efficacious multiple
myeloma treatment previously licensed for use
in relapsed and refractory disease. It was
licensed in the EU as a first-line therapy in
2015, and in light of data from the FIRST study
[3, 4], it is likely to become the standard of
first-line care for patients with multiple
myeloma. In patients with newly diagnosed
transplant-ineligible multiple myeloma,
continuous lenalidomide–dexamethasone was
superior to melphalan, prednisone, and
thalidomide (MPT) (72 weeks) for all primary
and secondary efficacy endpoints, including OS,
at the time of final analysis of primary
endpoint, PFS. OS at 4 years was 59% with
continuous lenalidomide–dexamethasone, 56%
with 18 cycles of lenalidomide–dexamethasone,
and 51% with MPT [5]. Further analysis showed
that median OS was 58.9, 56.7, and
48.5 months for patients treated with
continuous lenalidomide–dexamethasone, 18
cycles of lenalidomide–dexamethasone, and
MPT, respectively; for continuous
lenalidomide–dexamethasone, this represents a
10.4-month improvement in OS compared with
those receiving MPT [6]. The increased survival
benefit with lenalidomide was confirmed by
Weisel et al., who conducted a network
meta-analysis of survival in randomised
controlled myeloma trials; lenalidomide was
associated with a significant progression-free
and overall survival advantage versus other
first-line treatments (bortezomib, melphalan,
and prednisone [VMP] and MPT) [7]. In
addition to its favourable efficacy and
acceptable toxicity profile, lenalidomide is an
oral therapy requiring fewer hospital visits for
treatment administration compared with
alternative subcutaneous or intravenous agents
[8–10], making this a more acceptable and
better tolerated class of drugs.
Within the EU, a lenalidomide doublet
regimen will be standard of care for elderly
patients and those ineligible for autologous
stem cell transplantation, whilst triple therapy
regimens combining an immunomodulatory
drug and steroid with either a proteasome
inhibitor or a monoclonal antibody are
anticipated to become new standards of care
in the next 5 years for younger, transplant
eligible patients [3, 11–14].
In an era of increasingly cost-conscious
health systems, economic information,
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including resource use, plays an important role
in market access decision making for innovative
medicines. The objective of our study was to
assess the cost impact of lenalidomide when
selected as a first-line treatment for newly
diagnosed multiple myeloma patients in the
EU5 (France, Germany, Italy, Spain, and the
United Kingdom) versus current treatment
options. We hypothesised that lenalidomide is
likely to have a marginal incremental cost
burden in the EU5 at first-line; the increase in
OS and reduced administration costs compared
to other first-line therapies will delay those costs




To demonstrate the average time to progression
of an entire multiple myeloma care pathway,
treatment sequences that included
lenalidomide-based therapy in first line were
compared with treatment sequences that
included thalidomide- or bortezomib-based
regimens as first-line options.
Lenalidomide First-Line Uptake in the EU5
We developed a cost-impact model to estimate
the total costs associated with newly diagnosed
multiple myeloma over 5 years in the EU5. We
based this model on treatment duration and
time to progression data from several trials;
these outcomes also allowed us to model the
efficacy of multiple myeloma treatments. This
research is based on previously conducted
studies; it does not involve any new studies
involving human or animal participants, as
conducted by any of the authors. The current
EU standard of care for multiple myeloma in
autologous stem cell transplant-ineligible
patients at first-line is MPT or VMP, as advised
by the European Society of Medical Oncology
(ESMO) [1]. The model included drug,
administration, and hospitalisation costs of
first-line treatment and two more additional
lines of post-progression treatment for
lenalidomide-, thalidomide-, and
bortezomib-based regimens, as well as the
costs of fourth-line pomalidomide-based
regimens, based on expected clinical practice.
We sourced hospitalisation costs from a
retrospective chart review of Dutch patients
with relapsed/refractory multiple myeloma [10].
We adapted these costs to the first-line setting
by adjusting for the duration of treatment (DoT)
and the time to progression (TTP) as reported in
the clinical trials of each regimen (shown in
Table 1). It is worth noting that DoT data may
also include treatment-free intervals associated
with some treatments. The model has been
designed using TTP data; time to next treatment
data were not available within the trials because
of the variability in starting a new treatment
line.
Drug costs were calculated according to drug
prices and dosing (i.e., the number of doses per
month multiplied by the total mg per dose
multiplied by the cost per mg). Weighted averages
were used to calculate listed drug prices across the
EU5. Monthly costs within the line of treatment
were equated to the sum of hospital-based costs
(visits, admission, procedures, concomitant
medication) as published by Gaultney et al. [10].
Hospital costs in the first-line treatment setting
were not described by Gaultney et al.; therefore,
hospital costs in the second-line treatment setting
were adjusted to TTP and applied to first-line use,
assuming the samemonthly cost during treatment
time.
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We compared a baseline scenario (of current
lenalidomide uptake) with two alternative
future scenarios. The baseline scenario
reflected the estimated current uptake of
first-line lenalidomide (i.e., 11% of the
market). For Future Scenario A, we assumed a
steadily increasing uptake of first-line
lenalidomide: up to 50% in Year 5. The
baseline 11% market share for lenalidomide
was taken from bortezomib-based and
thalidomide-based regimens so that,
proportionally, the relative market share of
these two comparators remained the same.
Table 2 shows the baseline scenario and
assumed market share of therapies at first line.
Table 3 shows the market share overrides after
first-line therapies for Future Scenario A.
Scenario Estimating Potential Impact
of Triple Therapy
Future Scenario B was identical to baseline
scenario, but we also assumed a 20% increased
uptake of carfilzomib-based triple therapy
(KRd) at second-line. Furthermore, a small
percentage of patients in both future
scenarios were assumed to receive a
re-treatment. For example, VMP after first-line
Table 1 Duration of treatment and efﬁcacy of each regimen in each line







1 Thalidomide 15.4 21.2 23.9 FIRST trial [5]
Bortezomib 10.6 21.7 24.0 VISTA trial
[15]
Lenalidomide 18.4 25.5 32.5 FIRST trial [5]
2 Thalidomide 6.4 7.3 8.0 Kropff et al.
[16]
Bortezomib 7.0 8.1 (DoR) 7.0 Richardson
et al. [17]
Lenalidomide 12.5 14.1 17.1 Stadtmauer
et al. [18]
3 Thalidomide 6.4 7.3 7.0 Kropff et al.
[16]
Bortezomib 4.9 7.8 (DoR) 4.9 Richardson
et al. [17]
Lenalidomide 9.2 9.5 10.6 Stadtmauer
et al. [18]
4b Pomalidomide 2.9 4.6 3.6 MM-008 trial
CSR
CSR clinical study report, DoR duration of response
a Time to progression given as median
b Pomalidomide-based regimens assumed to be used exclusively after third line
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VMP; there is a precedent for this in clinical
practice with bortezomib-based regimens [19].
Table 2 shows the baseline scenario and
assumed market share of therapies at first-line
and Table 3 shows the market share overrides
for Future Scenario A. Table 4 shows the
market share overrides after first-line therapies
for Future Scenario B.
Table 2 Assumed market share of therapies in ﬁrst-line setting
Treatment regimen Model scenario market shares
Baseline scenario (%) Future Scenario A
Year 1 (%) Year 2 (%) Year 3 (%) Year 4 (%) Year 5 (%)
Thalidomide 25 19 17 16 15 14
Bortezomib 64 53 48 44 40 36
Lenalidomide 11 28 35 40 45 50
Table 3 Market share overrides after ﬁrst-line for Future Scenario A
Treatment regimen Model scenario market sharesa
After ﬁrst-line After second-line
THAL (%) BORT (%) LEN (%) THAL (%) BORT (%) LEN (%)
Thalidomide 7 14 17 4 21 36
Bortezomib 37 25 71 30 13 58
Lenalidomide 56 61 12 66 66 6
BORT bortezomib, LEN lenalidomide, THAL thalidomide
a Pomalidomide-based regimens assumed to be used exclusively after third line; some patients were assumed to receive a
re-treatment, e.g., MPT after ﬁrst-line MPT
Table 4 Market share overrides after ﬁrst-line for Future Scenario B
Treatment regimen Model scenario market sharesa
After ﬁrst-line After second-line
THAL (%) BORT (%) LEN (%) THAL (%) BORT (%) LEN (%) CAR (%)
Thalidomide 5 11 17 4 21 36 39
Bortezomib 26 20 63 30 13 58 61
Lenalidomide 39 39 10 66 66 6 0
Carﬁlzomib 30 30 10 0 0 0 0
BORT bortezomib, CAR carﬁlzomib, LEN lenalidomide, THAL thalidomide
a Pomalidomide-based regimens assumed to be used exclusively after third-line; some patients were assumed to receive a
re-treatment, e.g. thalidomide after ﬁrst-line thalidomide
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RESULTS
Compared with alternative first-line care
pathways, our model results demonstrated that
first-line lenalidomide provides a time to
progression advantage of up to 5.1 months
over a patient’s lifetime (when averaging all
treatment pathways), as is shown in Fig. 1.
In the baseline scenario, the annual costs per
patient were €40,692 in Year 1. In Future
Scenario A, we replaced the current first-line
standard of care with lenalidomide; in Year 1,
this resulted in an additional expenditure of
€867 per patient, which represents a 2.1%
increase from the baseline scenario. By Year 5,
the additional expenditure in Future Scenario A
increased to €3358 per patient, an 8.2% increase
from baseline. The cost per patient of using
lenalidomide at first-line in the EU5 is shown in
Fig. 2. Lenalidomide-treated patients had higher
monthly drug costs per patient (€5388)
compared with patients receiving bortezomib
(€3381) or thalidomide (€1742). However,
lenalidomide use was associated with a lower
monthly hospitalisation cost per patient (€813)
compared with bortezomib (€1173) and
thalidomide (€1532). Monthly hospitalisation
costs were calculated on the basis of ‘‘total cost
in line of therapy’’—this value was derived from
the monthly costs within the line of treatment
multiplied by the TTP for each treatment arm.
Monthly costs within the line of treatment were
the sum of hospital based costs published by
Gaultney et al. [10].
In Future Scenario B, we modelled a 20%
uptake of the novel triplet combination KRd at
second line; we estimated that the impact on
the budget will represent an additional 29%
increase over the current baseline scenario. In
contrast, modelling a future care pathway with
increasing first-line lenalidomide resulted in a
budget impact of only 8% over the current
baseline, as shown in Fig. 3.
DISCUSSION
Our results show that the availability of
lenalidomide at first-line has a relatively small
impact on budget, i.e., an 8% increase. This
increase should be considered both within the
context of the increased benefit expected for
patients in terms of TTP and OS, and when
compared to the potential impact of
introducing triple combination therapy with a
novel agent as first-line salvage for the 20% of
patients we estimated to be fit enough to receive
this treatment later in their treatment pathway
(29% increase in budget impact). Not all
patients are eligible for triple therapy during
subsequent lines of treatment; this is especially
relevant in the context of an increasingly
elderly population. Although there are no
direct, randomised data comparing Rd and
VMP, lenalidomide is expected to be more
Fig. 1 Treatment efﬁcacy (DoT, TTP, months). BORT
bortezomib, DoT duration of treatment, LEN lenalido-
mide, THAL thalidomide, TTP time to progression.
Cross-hatching represents the time spent off-treatment
before progression. This varies between treatments because
they have either a ﬁxed DoT or a dose intervention
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effective than current first-line therapies, as
suggested by the FIRST trial results and
supported by the indirect comparison of
treatments conducted by Weisel et al. [5–7].
Using lenalidomide, therefore, delays the time
to subsequent therapy because of its
improvement in time to progression compared
to other first-line therapies, but we are aware
that the duration of treatment may vary across
countries, which may further affect treatment
efficacy. The reduction in requirement for
subsequent therapy reduces costs for
administration and hospitalisation due to
toxicities; this contributes to off-setting the
increased drug cost of lenalidomide use. Our
results also show that reserving lenalidomide
for a later line such as combination with a novel
triple therapy combination (KRd) will increase
the budget by 29% compared to the current
baseline scenario.
Our findings agree with those from Arikian
et al., who used US healthcare data to show
that, for the first 3 years of treatment, patients
who initiated lenalidomide-based treatments
had lower mean monthly total costs compared
to those who initiated on bortezomib-based
treatments [8]. Arikian et al. also demonstrated
that the cumulative cost of first-line
lenalidomide was approximately $120,000
(€109,000) lower than for first-line bortezomib
[8]. These findings further support our
recommendation that the most beneficial way
Fig. 2 Annual cost per patient receiving ﬁrst-line lenalidomide in the EU5 for Future Scenario A. EU5 France, Germany,
Italy, Spain, and the United Kingdom
Fig. 3 Per-patient costs in Year 5 of baseline and future scenarios in the EU5. 1L ﬁrst-line, 2L second-line, EU5 France,
Germany, Italy, Spain, and the United Kingdom, LEN lenalidomide, KRd carﬁlzomib, lenalidomide, and dexamethasone
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to use lenalidomide for patients with newly
diagnosed multiple myeloma is at first-line thus
capitalising on its increased time to
progression/OS and cost impact compared to
other choices of first-line treatment.
Our results suggest that compared to other
first-line therapies, appropriately selecting
patients to receive first-line lenalidomide
would have a reduced cost impact, as well as
better OS and tolerability. Many of these
patients, who are too frail to tolerate triplet
combinations upfront, are unlikely to become
more suitable upon relapse.
The costs of managing toxicity both to the
patient and the healthcare system should also
be carefully considered. Myelosuppression,
which occurs more frequently with triplet
therapies, does have a significant cost impact
when treatment with blood products or growth
factors is required. One limitation of this study
is that it did not assess the costs associated
with patient side-effects from treatment. As
these data were not available for all
comparators, we only assessed the impact on
hospitalisation. However, given the relatively
similar side-effect profiles between the
treatments, this was not believed to
significantly affect the conclusions of the
model. Another limitation of our study is
that data are taken from a variety of sources
in order to estimate the likely economic
impact of future treatment scenarios. In
particular, data for hospitalisation were taken
from a retrospective analysis, which increases
the risk of bias or confounding.
Further research to evaluate the complete
direct and indirect costs of multiple myeloma
treatment across all treatment lines would
further improve the understanding of the
economic impact of this disease. As yet, there
are no available real-world data to guide patient
selection for therapies to improve both
long-term patient outcomes and reduce the
impact on EU5 healthcare systems.
Conducting cost-impact analyses may be
advantageous for understanding the budget
impact implications of new and/or expensive
oncology therapies and patient pathways,
particularly within disease areas where there
are multiple potential sequences of treatments
that could present a viable option for patients.
Selecting the most appropriate treatment
up-front is likely to be even more important in
the future, when new, more expensive
treatment regimens for relapsed multiple
myeloma become available. This will help
reduce and optimise the burden to healthcare
systems and ensure that these treatments are
available to the patients who would benefit the
most. Arikian et al. have demonstrated the
economic benefits of delaying first progression
in multiple myeloma in the US healthcare
setting [8]; it is limiting to multiple myeloma
patients that this is not an option in the EU.
Further research on the benefit to both patients
and the healthcare system of delaying first
progression is, therefore, also warranted.
CONCLUSION
Using lenalidomide in the first-line setting
delays the time to subsequent therapy
compared to other first-line treatments. It
offers substantial cost offsets due to the
reduced requirement for subsequent therapy,
lowering the costs associated with
administration and hospitalisation.
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